{"name":"Keros Therapeutics","slug":"keros","ticker":"KROS","exchange":"NASDAQ","domain":"kerostx.com","description":"Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain der","hq":"Lexington, MA","founded":0,"employees":"78","ceo":"Jasbir Seehra","sector":"Hematology Biotech","stockPrice":10.73,"stockChange":-1.26,"stockChangePercent":-10.51,"marketCap":"$212M","metrics":{"revenue":244060992,"revenueGrowth":-87.3,"grossMargin":47.9,"rdSpend":129643000,"netIncome":87014000,"cash":287415008,"dividendYield":0,"peRatio":4.7,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"KRT-232 patent cliff ($0.0B at risk)","drug":"KRT-232","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Dose A KER-012","genericName":"Dose A KER-012","slug":"dose-a-ker-012","indication":"Other","status":"phase_2"},{"name":"Dose B KER-012","genericName":"Dose B KER-012","slug":"dose-b-ker-012","indication":"Treatment of hypoparathyroidism","status":"phase_2"},{"name":"Dose C KER-012","genericName":"Dose C KER-012","slug":"dose-c-ker-012","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Dose A KER-012","genericName":"Dose A KER-012","slug":"dose-a-ker-012","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Dose B KER-012","genericName":"Dose B KER-012","slug":"dose-b-ker-012","phase":"phase_2","mechanism":"Dose B KER-012 is a bone morphogenetic protein (BMP) agonist.","indications":["Treatment of hypoparathyroidism"],"catalyst":""},{"name":"Dose C KER-012","genericName":"Dose C KER-012","slug":"dose-c-ker-012","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Keros Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Keros Therapeutics reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Keros Therapeutics Announces Collaboration with Leading Research Institution","summary":"Keros Therapeutics announced a collaboration with a leading research institution to advance its pipeline of hematology therapies.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"trial","headline":"Keros Therapeutics Announces Positive Interim Results from Phase 2 Clinical Trial of KRT-232","summary":"Keros Therapeutics announced positive interim results from a Phase 2 clinical trial of its lead product, KRT-232, in patients with myeloproliferative neoplasms.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSE9UdnBCS1FpdG81QVVPeGNGM3lEZmFWeXlrMXltb0ZOa2lUZlg0OFdPdHVKQVdBR3BtbUsxNmFwbU5qS3ZMSUZTMXdDb25uYVRiX01iZkE4a1NkTG1VY1l2eHJmUy1sSnZickpqYm5oaWNlYXdCckJvMF9NYTItSjNTa1Y5Vng4MmFuWGRILWgwTGgxa0UzUWI5STR5bmgzREp3U2lnMy1BX3ZwY2FwWG0xU3hQT2pGSGRmWlVn?oc=5","date":"2026-02-18","type":"earnings","source":"TradingView","summary":"Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView","headline":"Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPSTN6VC1YLWpMbTNRbHVVNVhra3hRY3A5Ukx3ejNtTm5ZOWhFSC1kOGhxMUEyN1FucTFJRGJaczc4QlBiVmVsSWJUYXVYMkpHWHYyeHlTdHl1ZjVlamJyb3oxWl9mcmNvbVB6RThwTkQxX1JVbTZhQURiSFVJcFB1NjR3T0llSVRqdy1yRXYzMWFWWTRtUFE4?oc=5","date":"2026-01-15","type":"pipeline","source":"Finviz","summary":"KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz","headline":"KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-18","type":"pipeline","source":"simplywall.st","summary":"Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st","headline":"Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPUnlJQUlKRGFvOFk2Y0hCbkxIcVpFVTRYay1SSkNHZmw1RzZjUlQ5d2U5SURLaDhnd1pTNWFkOGlKTkdsaHlDMDFMVGNEUmJydUotQmRyck8xTVNhOHY4V0w3WGZhcFVnZEFBYnU3RlBjTVppa0d4Um1FbTEyLVpmeEdfdlptSjFUZHc?oc=5","date":"2025-09-25","type":"pipeline","source":"Seeking Alpha","summary":"Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha","headline":"Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-29","type":"pipeline","source":"simplywall.st","summary":"Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being - simplywall.st","headline":"Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQUC01Y3RQRU1iWXFWa283dzNUdE0yOU1hR0hPbnFHMjZDWXJQZ1NxNlJLS2hENEpwNFF4TVRLMThxYzRCX2lfbzRLYTRPUnJEb19oVzQ0end4VDhKYXFENUlWODFwU2NwcW03UUNMa0xoVkd6eGo3NFkydnp1RFJpemhEenBpOFQtWkNsaUVWVk9TR0pLVzhyd2RWY2s0OTdYY2lNem9GeXVyU0VGcGMzeWRCN0JDaHlnUDc4TVhqOURiV2xBMXlaRGZWcVF0SGhxX0d3ZkthdUJ5SW81MWxHc0FR?oc=5","date":"2024-12-12","type":"trial","source":"Reuters","summary":"Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial - Reuters","headline":"Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSUVBU0N2WklPZ3RxOW03ZUl2ZU5JckNhQnBEUlJ6bmZObEdjWTdSdnoxVW4xU0Z5UGpUUXlJOHUtV3NuZ2VxYTl5TXNISUZCOWNabkc3SmNZMjJxYjVDMElIRzhldWJ5ckVmaElRMlhLbDhydG5wb0xIc0VMaEFvWWhRMzRRRGRkRkI3c2ZVS2xCTkRqaFNFQVhuS2RjV2MxN0ZBLUU1NjdRUlZoQ2pfZDVKV2x5Zw?oc=5","date":"2024-12-03","type":"pipeline","source":"MedCity News","summary":"Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond - MedCity News","headline":"Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNZDVmQmt1Z0NmNzE3bkthcTVwNUhFZGhjYjQ5Vm9UTDdEZnpjY2VDRHBtUG1idXl1R3ZTcWZFLWtQUWUteWswNHBOdERRY2RueXBkbWpCZVRHa2IyeEQ3alhZTTQwWHNRT2thb00yZ0ZiOWFZbTBiQmktVHE0eDJJTWhCbWx0bTlkZGl2aGRMeXN6eFZtNmFzVjBOeDJ4X0h5OHd6SXRtN0xkSXRTbjBRZHk3SDRreE1KbFhpRExOdTFTR2MtQjU0enh2V1ktUWFoZHIxUEszbkdEVGFkU3d3TmhTbUZRRnVSVlpUd0tpS0pJQQ?oc=5","date":"2024-12-03","type":"deal","source":"globenewswire.com","summary":"Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept - globenewswire.com","headline":"Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQQXNaUkdVM0NsTk9qXzFWaGs5aFFxNzBEcS1BOGUzLS05elU1Q25OLXJMOUNJMXNVTVUzVURVUHltOHhCYmpvNy1sVnFjQV9GNGhPSkhMdmxGQnVid1JucmJwc0pUQnF6dFJLcG9RZ24xTzJlTXhOQmJuZmctb193SWp1YmlEcTdjTE54YVk4aDVDeDc4V0xGZDZFY3JpbnF2NmdZN2RpSWQ2dWltT1JyRWNKRm5lQV9CcXE5ZTFFM3ViNGcwcHZkelFQNWVYQXNWdkxRMDE0Mm5mZjB6OFd1YnVRbHRmNVBaMk1HRmRmdVl1VDNP?oc=5","date":"2024-12-03","type":"pipeline","source":"Business Wire","summary":"Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Business Wire","headline":"Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNZXhFVllqbmpHRmpseDNlb1ZDOXlNZnVvRTViQ21PdDNHejVlOFA4OEFZajlfbEZtQW5PejRzbUpsOGZxT2EyTHFtQjdsMkRTTGptdlJSSGRKcnRnUXBneDJZbzV1WV9EbE5iOGdnZ29uRXhBcF9TM3VmZ0dSVHJzcGFzMGwtLW1CcFJpNnNKbFlZUVRwaHRSSFljM096S0F3ZVo5OGVpM2JTNlhHLXZKdVRRYw?oc=5","date":"2024-01-09","type":"trial","source":"Moomoo","summary":"NHP data from $Regeneron Pharmaceuticals (REGN.US)$ 's new slide deck is very relevant for the weight loss space. - Moomoo","headline":"NHP data from $Regeneron Pharmaceuticals (REGN.US)$ 's new slide deck is very relevant for the weight loss space.","sentiment":"neutral"}],"patents":[{"drugName":"KRT-232","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Incyte Corporation","Gilead Sciences","Bristol Myers Squibb"],"therapeuticFocus":["Hematology","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":243864000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":243864000,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":129643000,"rdSpendHistory":[{"period":"2025-12-31","value":129643000},{"period":"2024-12-31","value":173629000},{"period":"2023-12-31","value":135258000},{"period":"2022-12-31","value":87265000}],"sgaSpend":46849000,"operatingIncome":67569000,"operatingIncomeHistory":[{"period":"2025-12-31","value":67569000},{"period":"2024-12-31","value":-209595000},{"period":"2023-12-31","value":-167541000},{"period":"2022-12-31","value":-107709000}],"netIncome":87014000,"netIncomeHistory":[{"period":"2025-12-31","value":87014000},{"period":"2024-12-31","value":-187353000},{"period":"2023-12-31","value":-152992000},{"period":"2022-12-31","value":-104679000}],"eps":-5,"epsHistory":[{"period":"2024-12-31","value":-5},{"period":"2023-12-31","value":-5.2},{"period":"2022-12-31","value":-4.15},{"period":"2021-12-31","value":-2.52}],"cash":287415000,"cashHistory":[{"period":"2025-12-31","value":287415000},{"period":"2024-12-31","value":559931000},{"period":"2023-12-31","value":331147000},{"period":"2022-12-31","value":279048000}],"totalAssets":338021000,"totalLiabilities":34889000,"totalDebt":16883000,"equity":303132000,"operatingCashflow":107505000,"operatingCashflowHistory":[{"period":"2025-12-31","value":107505000},{"period":"2024-12-31","value":-160869000},{"period":"2023-12-31","value":-124508000},{"period":"2022-12-31","value":-70062000}],"capex":-1551000,"capexHistory":[{"period":"2025-12-31","value":-1551000},{"period":"2024-12-31","value":-1931000},{"period":"2023-12-31","value":-2464000},{"period":"2022-12-31","value":-1241000}],"freeCashflow":105954000,"dividendsPaid":null,"buybacks":-375000000,"employees":78,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":11743000,"ebit":-29270000,"ebitda":-28870000,"period":"2025-12-31","revenue":385000,"epsBasic":-0.86,"netIncome":-23461000,"rdExpense":17912000,"epsDiluted":-0.86,"grossProfit":null,"operatingIncome":-29270000},{"sga":10127000,"ebit":-15384000,"ebitda":-14989000,"period":"2025-09-30","revenue":14262000,"epsBasic":-0.18,"netIncome":-7280000,"rdExpense":19519000,"epsDiluted":-0.18,"grossProfit":null,"operatingIncome":-15384000},{"sga":14482000,"ebit":-39817000,"ebitda":-39447000,"period":"2025-06-30","revenue":18168000,"epsBasic":-0.76,"netIncome":-30696000,"rdExpense":43503000,"epsDiluted":-0.76,"grossProfit":null,"operatingIncome":-39817000},{"sga":10497000,"ebit":152040000,"ebitda":152384000,"period":"2025-03-31","revenue":211246000,"epsBasic":3.66,"netIncome":148451000,"rdExpense":48709000,"epsDiluted":3.62,"grossProfit":null,"operatingIncome":152040000},{"sga":10665000,"ebit":-29474000,"ebitda":-29142000,"period":"2024-12-31","revenue":3042000,"epsBasic":-1.14,"netIncome":-46026000,"rdExpense":45631000,"epsDiluted":-1.14,"grossProfit":null,"operatingIncome":-52016000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":10.73,"previousClose":11.99,"fiftyTwoWeekHigh":22.55,"fiftyTwoWeekLow":10.32,"fiftyTwoWeekRange":"10.32 - 22.55","fiftyDayAverage":11.51,"twoHundredDayAverage":15.46,"beta":0.95,"enterpriseValue":-34118780,"forwardPE":-2.1,"priceToBook":0.69,"priceToSales":0.87,"enterpriseToRevenue":-0.14,"enterpriseToEbitda":-0.47,"pegRatio":0,"ebitda":72078000,"ebitdaMargin":29.5,"freeCashflow":66236624,"operatingCashflow":107505000,"totalDebt":16883000,"debtToEquity":5.6,"currentRatio":15.45,"returnOnAssets":9.2,"returnOnEquity":19.9,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":21.83,"targetHighPrice":30,"targetLowPrice":16,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.6,"institutionHeldPercent":107.7,"sharesOutstanding":19787837,"floatShares":19119697,"sharesShort":1415972,"shortRatio":4.14,"shortPercentOfFloat":7.2,"epsTrailing":2.3,"epsForward":-5.08,"revenuePerShare":6.56,"bookValue":15.51,"officers":[{"age":69,"name":"Dr. Jasbir S. Seehra Ph.D.","title":"President, CEO & Director"},{"age":55,"name":"Mr. Keith C. Regnante MBA","title":"Chief Financial Officer"},{"age":36,"name":"Ms. Esther  Cho J.D.","title":"Chief Legal Officer & Secretary"},{"age":53,"name":"Dr. Lorena  Lerner Ph.D.","title":"Chief Scientific Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.kerostx.com","phone":"617 314 6297"}}